Advancing Autologous Biologics for the Future of Healthcare
Advancing Autologous Biologics for the Future of Healthcare
Maximizing Regenerative Capacity
At Cervos, we believe that ‘dose matters’—a philosophy that defines our mission of delivering superior biologics. Developed hand in hand with leading physicians, our products are designed to economically offer the highest level of efficacy, usability and safety.
Our Products
Minimally Invasive, Maximally Efficient, and Cost-effective Autologous Biologic Solutions for Advanced Care
KeyPRP
High-dose platelet-rich plasma
Marrow Cellution
Centrifuge-free bone marrow harvesting
IO Access
Drill Enabled Intraosseous access cannulas
Lipo-Pro
High-density adipose grafting system
Our Products
Minimally Invasive, Maximally Efficient, and Cost-effective Autologous Biologic Solutions for Advanced Care
Clinically Proven Regenerative Results
“In the first 2 months, patients who received the PRP were showing significant improvements in pain and function, whereas the control group was not…Intradiscal LR-PRP effectively decreased the fusion rate by roughly 80% in this group of patients.”
Lutz February 2023 Intradiscal Leukocyte Rich PRP for Degenerative Disc Disease 
“The Cervos KeyPRP system consistently produces higher platelet yield with a minimal hematocrit and a favorable Agranulocyte/Granulocyte Ratio. The system is secure, it is closed to [the] external environment, and can afford the clinician the ability to customize the various blood fractions as specifically desired.”
Kyriakides July 2022 Platelet Rich Plasma (PRP) / Platelet Concentrate (PC) Systems: Preparation Processing Protocols
“Patients treated with BMA have superior changes in Quick-DASH & EQ-5D-5L pain and health scores (12-month post injection) when compared to patients treated with cortisone.”
Injection of Bone Marrow Aspirate for Glenohumeral Joint Osteoarthritis: A Pilot Randomized Trial– T. Dwyer, MD
“The [BMA] device obviates the pitfalls of legacy needles and subsequent centrifugation…As a result, the need for centrifugation is eliminated, thereby dramatically reducing the total amount of time required to perform the therapeutic procedure, significantly reducing the need for staff to process the aspirate, and ultimately yielding a favorable autologous orthobiologic product.”
Small Draw, Diverse Geography, Precise Repositioning, Lateral Draws Only, Pace, and Syringe Plunger Yields Clinically Relevant CFU-f Counts– P.D. Tortland, DO
“The MC Device, using the SSLM draw technique, produced concentrations of CFU-fs, CD34+ cells and CD117+ cells that were comparable or greater to BMACs derived from the same patient. Given the rapid speed and simplicity of the MC Device, we believe this novel system possesses significant practical advantages to other currently available centrifugation-based systems”
Scarpone January 2019 Isolation of Clinically Relevant Concentrations of Bone Marrow Mesenchymal Stem Cells Without Centrifugation
Previous
Next
Optimize Natural Healing. Empower Long-Term Relief.
Schedule a product demo to discover the easier way to improve your patient outcomes.
